ALPHAMAB ONCOLO.DL-000002 (3NK) — Cash Flow Reinvestment Rate

Latest as of December 2024: 0.76x

ALPHAMAB ONCOLO.DL-000002 (3NK) has a Cash Flow Reinvestment Rate of 0.76x as of December 2024, reinvesting €161.11 Million (capex €21.77 Million plus investments €-139.34 Million) from operating cash flow of €212.34 Million. Check earnings quality score of ALPHAMAB ONCOLO.DL-000002 to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.76x

(Capex + Investments) / Operating CF

Total Reinvested

€161.11 Million

Capex + Investments

Operating Cash Flow

€212.34 Million

EUR

Capital Expenditures

€21.77 Million

EUR

ALPHAMAB ONCOLO.DL-000002 Cash Flow Reinvestment Rate (2024–2024)

Historical reinvestment intensity for ALPHAMAB ONCOLO.DL-000002 across 1 annual periods. Explore debt repayment capacity of ALPHAMAB ONCOLO.DL-000002 to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for ALPHAMAB ONCOLO.DL-000002 (2024–2024)

Year-by-year capital reinvestment analysis for ALPHAMAB ONCOLO.DL-000002. For live market cap and broader valuation context, see ALPHAMAB ONCOLO.DL-000002 stock valuation.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2024	0.76x	€161.11 Million	€212.34 Million	€21.77 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow